Pharmaceutical
Integrity Platform
A licensing platform addressing two fundamental constraints: molecular instability and lifecycle discontinuity in plant-derived and complex bioactive compounds.
Two Core Challenges Limiting
Pharmaceutical Success
Performance Variability
- Molecular instability
- Inconsistent pharmacokinetics
- Variable clinical outcomes
- Difficulty in FDA study replication
Integrity and Trust Gaps
- Counterfeit and diverted products
- Lack of product-level verification
- Undetected tampering or handling failures
- Fragmented supply chain visibility
A unified approach to
pharmaceutical integrity.
HyGyHya has developed a licensing platform that addresses both challenges through a unified Pharmaceutical Integrity Platform. Two complementary engines — deployed independently or integrated — provide end-to-end consistency from formulation through patient use.
Two Engines. Independent or Integrated.
Performance Integrity
Stabilization Engine
- Preserves molecular structure and function
- Protects against environmental and chemical degradation
- Enables consistent pharmacokinetic behavior
- Improves absorption and biological utilization
Result
More predictable performance and reduced variability in clinical outcomes
Verification and Trust Infrastructure
Product Integrity Engine
- Establishes persistent product identity
- Enables lifecycle authentication
- Detects inconsistencies and tampering
- Supports traceability across supply chains
Result
Verified authenticity, reduced counterfeit risk, and improved compliance
Performance + Trust
Across the Lifecycle
When deployed together, the two engines create a unified Pharmaceutical Integrity Platform addressing both core dimensions of pharmaceutical reliability.
End-to-end consistency
From formulation through patient use, both performance and identity are maintained.
Reduced variability
Stabilization reduces pharmacokinetic variability while integrity systems reduce supply chain risk.
Increased confidence
Partners, regulators, and patients gain confidence in both what the product does and what it is.
Validation
Internal validation has demonstrated consistent and repeatable performance across controlled evaluation environments relevant to pharmaceutical applications.
- Preservation of compound integrity under degradation-inducing conditions
- Improved consistency in pharmacokinetic-related outcomes
- Reliable detection of controlled inconsistencies in product identity
- Repeatable system behavior across varied test conditions
- Maintained biological performance over extended timeframes
Detailed validation materials are available under confidentiality agreement.
Flexible Licensing Platform
HyGyHya operates as a licensing platform with multi-asset applicability. Partners integrate either or both engines through flexible licensing structures.
- Independent licensing of either engine for specific programs
- Integrated deployment for end-to-end pharmaceutical integrity
- Scalable across therapeutic areas and geographies
- Compatible with existing manufacturing infrastructure
- B2B model for pharmaceutical manufacturers and strategic partners
Request Technical Materials
Detailed technical information, validation data, and platform architecture are available under appropriate confidentiality agreements.
Platform questions
Yes. Each engine is designed to deliver standalone value. The Stabilization Engine can be independently licensed for drug development programs. The Product Integrity Engine can be independently deployed across manufacturing and distribution systems.
When deployed together, the platform provides end-to-end consistency from formulation through patient use — addressing both performance integrity and product integrity across the pharmaceutical lifecycle.
Internal validation has demonstrated preservation of compound integrity under degradation-inducing conditions, improved consistency in pharmacokinetic-related outcomes, reliable detection of controlled inconsistencies, and repeatable system behavior across varied test conditions.
Detailed technical information, validation data, and platform architecture are available under appropriate confidentiality agreements. Use the Contact page to request access.